BFC Planning’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
Other funds holding LGND
BFC Planning's LGND Position: Q3 2026 in Review
BFC Planning held its Ligand Pharmaceuticals (LGND) position steady in Q3 2026 at 9 shares worth $2.81K. The position accounts for ﹤0.01% of the portfolio, ranked #2908.
BFC Planning first reported a position in LGND in Q4 2025 and has held it in 4 quarters since. The position peaked at $2.84K in Q2 2026. 348 funds tracked by Wall St. Rank hold LGND as of Q3 2026.
- BFC Planning held 9 shares of Ligand Pharmaceuticals worth $2.81K as of Q3 2026.
- BFC Planning left its Ligand Pharmaceuticals share count unchanged in Q3 2026.
- Ligand Pharmaceuticals made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2908 holding.
- BFC Planning first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
- BFC Planning's Ligand Pharmaceuticals position peaked at $2.84K in Q2 2026.
- 348 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.